Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable
This study is being performed to evaluate the safety and tolerability of TRC102 in
combination with Alimta. In addition to safety, this study will also evaluate
pharmacokinetics and tumor response.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the recommended Phase 2 dose and overall safety and tolerability of TRC102 when given alone and when combined with pemetrexed for the treatment of patients with advanced solid or metastatic cancer for whom curative therapy is unavailable.
Bryan Leigh, MD
Tracon Pharmaceuticals Inc.
United States: Food and Drug Administration
|Phoenix, Arizona 85012|
|Fountain Valley, California 92708|
|Cleveland, Ohio 44195|